Image by Marina Vitale

Synergistic Blend of Standardized herbal extracts for Eye Health

MacOlene

Macolene - Eye health formula

MacOlene is a Patented, natural, synergistic  herbal composition developed for Eye health

Study involving ARPE and HUVEC cell line models in a single study, proves its benefits in AMD and diabetic retinopathy. It was found to downregulate VEGF secretion in ARPE (Retinal pigment epithelial cells) cells and also inhibits neovascularization in HUVEC cells

onlene2.png
Frau, die Augen überprüfen lässt

AMD is the main cause for heavy Vision in old age in the western Industrial countries.(1)

AMD concerns every fourth European over 60 years.(2)

AGE-RELATED MACULAR DEGENERATION DIASEAE PROGRESSION

Age-related macular degeneration (AMD) is an eye disease affecting the macula of the retina causing blurred vision or loss of central vision. AMD is one of the leading cause of vision loss in people over 50 years of age. It occurs in two forms, “Dry” form which is most common and “wet” form which is less common but more severe than the dry form and characterised by formation of neovascularization. VEGF (Vascular Endothelial Growth Factor) & PDGF (Platelet Derived Growth Factor) are major potent stimulators of wet AMD. While there is no specific treatment for AMD as such, vitamin combinations with lutein and zeaxanthin are found to be beneficial in the case of dry form and anti-VEGF intro-ocular injections are shown to be helpful in people with wet-AMD.

MECHANISM OF MACOLENE

MacOlene has the following machanism of action:

  • VEGF down-regulating activity

  • VEGF binding activity

  • PDGF inhibitory activity

  • Anti-neovascular

VEGF - Vascular Endothelial Growth Factor

PDGF - Platelet Derived Growth Factor

EFFICACY STUDIES

  • VEGF down-regulating activity in ARPE (Human Retinal Pigment Epithelial Cell lines)

  • VEGF binding activity in induced ARPE cell supernatant

  • Inhibition of formatio of new blood vessels in HUVEC
    (Human umbilical vein endothelial cells)

Efficacy of the MacOlene was proven through a cell line study using ARPE cells and HUVEC cells in the single study to mimic the in vivo pathophysiological conditions, where the ARPE cells are stimulated to produce VEGF, which is further used for stimulating HUVEC cells to form neovascularisation. MacOlene was show to have:

Image by Braňo

VEGF DOWN - REGULATING ACTIVITY OF MACOLENE

VEGF binding activity of MacOlene was evaluated in induced
ARPE cell supernatant containing VEGF.

  • VEGF downregulating activity of MacOlene was evaluated in ARPE cells

  • MacOlene was tested in two different dosage forms: Oral and Ophthalmic

  • There was a 58.49% and 59.38% downregulation of VEGF for oral and opthalmic formulation

nako_macolene_oralopthalmic.png

VEGF BINDING ACTIVITY OF MACOLENE

VEGF binding activity of MacOlene was evaluated in induced ARPE cell supernatant containing VEGF.

nako_macolene_oralopthalmic2.png
  • MacOlene was tested in two different dosage forms: Oral and Opthalmic
     

  • It achieved massive 83.98% and 70.58% binding of VEGF for oral and ophalmic formulation respectively

INHIBITION NEOVASCULARIZATION BY MACOLENE

Inhibition neovascularization by MacOlene was tested by inducing neovascularization in HUVEC cells using VEGF released from ARPE cells. MacOlene showed significant inhibition of tube formation observed in HUVEC cells

MACOLENE PRODUCTS

MACOLENE (Formula BASE)

MACOLENE PLUS - (Formula + Lutein + Zeaxanthin)


MACOLENE BERRY- (Forumla + Bilberry) - soon 

MacOlene is a trademark of Olene Life Sciences Pvt.Ltd., India
Registration of TMEU is pending

Image by Colin Lloyd